Rigel Pharmaceuticals Inc

24 авг. 2026 г., 19:56 UTC

Rigel Pharmaceuticals Inc shares are lower today, with no specific news identified for the decline. The stock remains above its 20-day moving average.

21 авг. 2026 г., 19:36 UTC

Rigel Pharmaceuticals Inc is trading higher, despite pulling back from an earlier session peak. The stock remains above its 20-day moving average.

20 авг. 2026 г., 20:06 UTC

Rigel Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday amid broader market pressures, though no specific news has been identified.

19 авг. 2026 г., 20:02 UTC

Rigel Pharmaceuticals Inc is trading higher amid strong market activity and high volume, reflecting increased investor interest since Tuesday's close.

18 авг. 2026 г., 22:01 UTC

Rigel Pharmaceuticals shares declined in after-market trading, dropping significantly amid broader market pressures from rising bond yields and inflation concerns.

17 авг. 2026 г., 20:06 UTC

Rigel Pharmaceuticals Inc. shares declined despite mixed analyst ratings updates. Piper Sandler raised its price target to $49, while H.C. Wainwright set it at $85.

14 авг. 2026 г., 20:06 UTC

HC Wainwright raised Rigel Pharmaceuticals' price target to $85, boosting investor sentiment. Shares are trading higher since Thursday's close amid mixed market conditions.

13 авг. 2026 г., 19:16 UTC

Rigel Pharmaceuticals shares decline following the launch of its breast cancer drug Veppanu, priced at $29,400 per month, amid safety concerns.

11 авг. 2026 г., 20:06 UTC

Rigel Pharmaceuticals Inc shares are higher in Tuesday's session, continuing gains from previous days amid routine fluctuations and no specific news driving the movement.

7 авг. 2026 г., 19:26 UTC

Rigel Pharmaceuticals reported EPS of $0.88, exceeding estimates. Revenue of $78.70 million also surpassed expectations, though analysts have mixed ratings on the stock.

6 авг. 2026 г., 20:06 UTC

Rigel Pharmaceuticals shares lower as the company in-licenses Veppanu for breast cancer treatment, projecting 2026 revenues of $285 million to $295 million.

5 авг. 2026 г., 20:02 UTC

Rigel Pharmaceuticals shares rise as the company reports Q2 EPS of $0.88, exceeding estimates, and raises full-year sales guidance to $285 million-$295 million.

4 авг. 2026 г., 23:01 UTC

Rigel Pharmaceuticals shares higher after reporting Q2 earnings of $0.88 and raising full-year sales guidance to $285 million to $295 million.

3 авг. 2026 г., 19:26 UTC

Rigel Pharmaceuticals Inc. is higher today, aligning with market trends as the S&P 500 and Nasdaq see gains amid improved investor sentiment.

31 июл. 2026 г., 19:41 UTC

Rigel Pharmaceuticals is lower today amid significant downward pressure in the Biotechnology sub-sector, despite a slight recovery from session lows.

30 июл. 2026 г., 19:29 UTC

Rigel Pharmaceuticals Inc shares are lower today amid unusual volatility, reaching a session low earlier after peaking shortly after the market opened.

29 июл. 2026 г., 19:47 UTC

Rigel Pharmaceuticals Inc. is trading higher Wednesday, pulling back from earlier session highs amid mixed performance across major U.S. indices ahead of the Fed's decision.

28 июл. 2026 г., 19:56 UTC

Rigel Pharmaceuticals shares are higher today as the company announced a conference call for its second quarter 2026 financial results on August 4.

27 июл. 2026 г., 16:16 UTC

Rigel Pharmaceuticals is higher during Monday's session, rebounding after six days of declines. The stock remains up since Friday's close amid broader market dynamics.

24 июл. 2026 г., 20:01 UTC

Rigel Pharmaceuticals Inc shares are higher today, recovering from earlier dips amid increased trading volume and broader market gains despite no specific news identified.

22 июл. 2026 г., 20:06 UTC

Rigel Pharmaceuticals Inc shares are lower Wednesday amid ongoing market uncertainty ahead of the Federal Reserve meeting, with no specific news driving the decline.

21 июл. 2026 г., 17:26 UTC

Rigel Pharmaceuticals Inc shares are higher, reflecting positive sentiment in the biotechnology sector amid broader market gains, particularly in technology stocks.